![Medical News Asia | Powered by ['mediPr]](https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png)
Navigating HER2 Testing: Unveiling the Strengths and Limitations to Optimize Biomarker Assessment
Due to the availability of human epidermal growth factor receptor 2 (HER2)-directed therapies, testing for HER2 alterations, including overexpression, gene amplification or mutations is recommended in treatment guidelines for various tumor types, including breast cancer, gastric cancer, biliary tract cancer, cervical cancer, colorectal cancer, non-small cell lung cancer (NSCLC), and others.1-10
Achieving the Best Outcomes under COVID-19 Endemicity
The first coronavirus (CoV) outbreak occurred as severe acute respiratory syndrome CoV in 2003 in China, followed by the emergence of the Middle East respiratory syndrome CoV in 2012.
Advancements in Nasopharyngeal Carcinoma Treatment: Insights from ASCO 2024
Despite advances in treatment, nasopharyngeal carcinoma (NPC) remains a significant health burden. Recent trials presented by ASCO 2024 explore the new treatment alternatives and efficacy of therapies.
Advancements in Hepatocellular Carcinoma Treatment: Insights from ASCO 2024
Hepatocellular carcinoma (HCC), is a devastating disease with limited treatment options. Recent trials presented by ASCO 2024 spotlight new findings on neoadjuvant immunotherapy, combination regimens for HCC, and efficacy of novel monotherapies.
